Prostate Cancer Prevention: The Role of PSA Testing, Biopsies and Newer Screening Techniques
The value of the PSA test has been brought under question by an advisory panel in the United States, but for the time being, there are few options for prostate cancer screening. Dr. William Catalona, a pioneer in developing the PSA test, stresses its continued importance, even when considering its imperfections. He also discusses newer tests that are becoming available to confirm a prostate cancer diagnosis that may help reduce the need for biopsies including a Magnetic Resonance Imaging (MRI) technique, the Pro-PSA blood test (recently approved in the European Union) and the new PCA3 urine test, now approved by the FDA.
Experts & Guests
William Catalona, M.D.
Director of the Clinical Prostate Cancer Screening Program, Northwestern Memorial HospitalWilliam J. Catalona, MD, is the director of the Clinical Prostate Cancer Program for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital. He is professor of Urology at Northwestern University’s Feinberg School of Medicine. In addition, Dr. Catalona serves as the Medical Director of the Urological Research Foundation. He is most widely known for... more >